Group
anti-EGFR/MET mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | anti-EGFR/MET antibody |
| Drugs in group | Amivantamab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No intrinsic radiosensitization for the naked antibody (blocks EGFR/MET survival + ADCC); though evidence is limited (Lavigne et al., European Journal of Cancer, 2026; Rodriguez-Castellanos et al., Cancer Research, 2026). Theoretical overlap of EGFR-mediated skin adverse events with radiation dermatitis exists (as with other EGFR agents), so in-field skin/mucosal reactions are a theoretical concern.
The data above refer to patients treated with anti-EGFR/MET mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.